Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 25.75M P/E - EPS this Y 15.70% Ern Qtrly Grth -
Income -14.58M Forward P/E -1.83 EPS next Y -137.10% 50D Avg Chg -21.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -37.00%
Dividend N/A Price/Book 4.37 EPS next 5Y - 52W High Chg -59.00%
Recommedations 2.00 Quick Ratio 2.50 Shares Outstanding 15.82M 52W Low Chg 16.00%
Insider Own 15.20% ROA -106.65% Shares Float 13.36M Beta -1.78
Inst Own 11.69% ROE -243.33% Shares Shorted/Prior 579.12K/294.47K Price 1.99
Gross Margin - Profit Margin - Avg. Volume 27,229 Target Price 12.09
Oper. Margin - Earnings Date May 15 Volume 26,749 Change 0.51%
About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Acurx Pharmaceuticals, Inc. News
05/02/24 Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference
04/25/24 Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference
04/23/24 Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update
03/21/24 Acurx Pharmaceuticals, Inc. Announces Participation in the LD Micro Invitational XIV
03/19/24 Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2023 Earnings Call Transcript
03/18/24 Q4 2023 Acurx Pharmaceuticals Inc Earnings Call
03/18/24 We Think Acurx Pharmaceuticals (NASDAQ:ACXP) Needs To Drive Business Growth Carefully
03/18/24 Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
03/04/24 Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update
02/27/24 Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development
02/23/24 New to The Street Announces Line-up of its Corporate Interviews Airing on its Leadership and Business Televised Series
02/16/24 New to The Street Airs Episode 556 Featuring Five Corporate Interviews, Broadcast on the FOX Business Network Monday, February 19, 2024, at 10:30 PM PT
02/02/24 New to The Street Announces its 553rd Episode TV Line Up, Featuring Five Corporate Guests, Airing on the FOX Business Network, Monday, February 5, 2024, 10:30 PM PT
02/01/24 New to The Street TV Announces Episode #552 with its Five Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, February 1, 2024, at 9:30 PM PT
01/29/24 Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
01/26/24 New to The Street Announces Episode 551, Five Corporate Interviews, Airing on the FOX Business Network, Monday, January 29, 2024, at 10:30 PM PT
01/23/24 Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024
01/19/24 New to The Street Airs on the FOX Business Network, Episode 550, Featuring Six Corporate Interviews, Broadcast Monday, January 22, 2024, at 10:30 PM PT
01/17/24 Why Is Antibiotic Player Acurx Pharmaceuticals Stock Trading Lower Today?
01/17/24 Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
ACXP Chatroom

User Image Dyslexiclad Posted - 1 day ago

$ACXP ya I'm actually shocked and bewildered that this has stayed above 2 this long

User Image hardcore_speculator Posted - 2 days ago

$ACXP UPDATE (new reported data + this months picture) The interesting ones reported today: # Group One Trading entered. # Vanguard added 85K. # LPL added 26K # BlackRock has dumped 44k -------------------------------------------- - LPL definitely added more at price levels similar to its first purchase, maybe a bit higher. Their avg price should be 1.8x, so these guys have a favorable position and betting for an upward move. - Vanguard's average price, according to my calculations should be 3.46 (below reported as 3.34). They have definitely lowered their average price. - BlackRock's average price cannot be below 3.7 with a plain vanilla buy and without active management. Lost 45% of their initial bet and now dumped 70% of their shares in this instead of lowering their average price like Vanguard. There can be many reasons for such a decision. -------------------------------------------- Why is $2.03 ±0.01 so important?

User Image hardcore_speculator Posted - 2 days ago

$ACXP BlackRock out. Owned this since Q3 2021 and liquidated without waiting for any improvement in the situation. LPL added more. One important thing to note: while "HealthCare" makes up 3.49% of LPL's portfolio, it makes 12.04% of BlackRock's portfolio.

User Image Mulhollandr Posted - 2 days ago

$ACXP if someone would be so kind to liquidate their position I have a few buy orders just a touch lower than the current price that I would like to see fill. Thanks. 👍🏻

User Image BIGTEXAN409MAGA Posted - 2 days ago

$ACXP sure wish we could get some news and have this thing pop! I dont even get invited to family reunions anymore since i talked family and friends into buying this.

User Image stayretired Posted - 2 days ago

$ACXP

User Image sean1122 Posted - 3 days ago

$ACXP Excellent leg work by Hardcore, very troublesome that these firms would sell a lot of their shares when we are supposedly so close to getting all the news about the FDA meeting and when the Phase 3 trial starts.....This is Troublesome, wouldnt surprise me if the CAR SALESMAN and the other Cronie have hoodwinked us all, the LOW volume that is trading daily, and the lack of anything meaningful from the Car Salesman are terrible signs really.

User Image hardcore_speculator Posted - 3 days ago

$ACXP Looks like a "few" out there are cutting losses. I'm pretty sure we will see more as time unfolds. If I am wrong, then it will be a win-win. If I am right, ... let's just hope I am wrong!

User Image SuperCool5000 Posted - 3 days ago

$ACXP Well damn. Good for them.

User Image hardcore_speculator Posted - 3 days ago

$ACXP Looks to me like an artificially raised price or the making of new bag holders. This gets more and more exciting. Invaluable experience. 5min Chart.

User Image hardcore_speculator Posted - 3 days ago

$ACXP Oh

User Image Jeff4iam Posted - 3 days ago

$ACXP at least our volume is a bit up compared to the last four days. However, the volume has largely been sells. I think some low volume shareholders have been liquidating, but doing it in smaller lots to keep price from dropping too far. My hope is that they end up regretting it in next two to three weeks.

User Image stayretired Posted - 3 days ago

$ACXP - wondering if anybody has been trading msgs with Luci in the past couple of weeks. And specifically the tone of his replies. I am pissed and wrote a nastygram yesterday. I don't expect a response, but it made me feel better to share what's on my mind.....

User Image cninc Posted - 3 days ago

$ACXP looks like we won't be getting any news before ER call because they just planned a new sit down interview with Biopub for May 17th.

User Image Delta69 Posted - 3 days ago

$ACXP "114" lots on Bid and Ask.... Seeing a lot of these which is nothing, but coincidental...

User Image geothug Posted - 4 days ago

$ACXP more cocktails for Dave!

User Image Pumpnddump Posted - 4 days ago

$ACXP we need the don back

User Image walltr8der Posted - 4 days ago

$ACXP We should get some updated news on the 15th of this month....

User Image Delta69 Posted - 4 days ago

$ACXP So = How is everyone doing? Let's talk about this volume - Crazy low... Anyways - Looking for another good entry point. I will play the expected news for this one... 30 days after meet so I am sure there will be a direction one way or another - and we are on diminishing timeline.

User Image Phil_Hertits Posted - 4 days ago

@thompske bro, you used to pump $ACXP 😂

User Image MarketForecasting Posted - 4 days ago

$ACXP looking like a inverse head and shoulders .

User Image MarketForecasting Posted - 4 days ago

$ACXP looking like a pair of ovaries on the daily , I wonder if hardheaded speculator charts see that .

User Image MarketForecasting Posted - 4 days ago

$ACXP If a 700 patient trial was ran knowing the numbers 25/26 , that means 27 patients out of 700 would feel less better then the remaining 673 . Not a bad ratio for a drug that can do wonders on the microbiome , but I would like To see microbiome data .

User Image Mulhollandr Posted - 4 days ago

$ACXP https://www.contagionlive.com/view/investigational-antibiotic-comparable-to-vancomycin-in-curing-c-diff

User Image hardcore_speculator Posted - 5 days ago

$ACXP Currently, dumb money is trading. No excitement but also no panic so far (despite some -$0.3 from the highs one week ago). Some increase in volume and at which level this volume appears (or does not appear!), will tell what to expect in the near future. Technicals doesn't look good. Only some unexpected news can stop this from dropping to 1.2x's. Hope I am wrong and you guys (some at least. I don't care about the cockroaches 🪳) make some money. Neither direction won't hurt me as I closed my position with a small profit before the meltdown, but I am looking for opportunities, bullish or bearish it doesn't matter.

User Image hardcore_speculator Posted - 5 days ago

$ACXP moves in a downward sloping channel whose origin can be traced back to Oct 23. It made some attempts and traded above that channel for a while (high volatility days) but it came back. It's last attempt to break out again was made in Feb24 but there wasn't sufficient power to sustain that move. Since then it has been stuck in this channel and could test 1.85 tomorrow, which by the way is not the lower bound of the channel but an intermediate projection of the channel boundaries which served as a support in the past. I'm also trying to gauge whether some smart money is buying but it doesn't look like that. In such a case we would see a declining price but the volume analysis would show a whole different picture. Last two days' candles are also important. Yesterday, despite a great high, it closed close near the open price. The optimistic mood was countered by a pessimistic one. Today's price closed at today's low, so yesterday's pessimism had the upper hand.

User Image hardcore_speculator Posted - 5 days ago

$ACXP Okay, it turns out they have some serious error in their system. ADN 's volume (according to some websites) was around 900k but IBKR reports it with 91.9M . MULN's volume should be 5.3M, but IBKR reports it with 542M. Interestingly some Volumes are correct.

User Image hardcore_speculator Posted - 5 days ago

$ACXP I trade with International Brokers. I don't expect them to make such a huge mistake but currently the volume on this is reported as 2.65M . Cross-validating with some data from the web, it's a huge bs. Yahoo says 26.1K, Investing 26.2K. hmm

User Image finallyfree22 Posted - 5 days ago

$ACXP More attention on Antimicrobial Resistance https://www.lelezard.com/en/news-21365669.html

User Image thefryingpan Posted - 6 days ago

$ACXP sleepiest board on ST

Analyst Ratings
HC Wainwright & Co. Buy Mar 19, 24
HC Wainwright & Co. Buy Feb 28, 24
HC Wainwright & Co. Buy Dec 15, 23
HC Wainwright & Co. Buy Nov 15, 23
HC Wainwright & Co. Buy Sep 13, 23
HC Wainwright & Co. Buy Aug 15, 23
HC Wainwright & Co. Buy May 15, 23
HC Wainwright & Co. Buy Apr 11, 23
HC Wainwright & Co. Buy Mar 17, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Sailer Carl Director Director Jan 19 Option 3.55 19,737 70,066 112,552 01/22/24
Sailer Carl Director Director Jul 27 Buy 3.80 19,737 75,001 92,815 07/29/22
DELUCCIA ROBERT J Director Director Jul 27 Buy 3.80 19,737 75,001 1,051,198 07/29/22
LUCI DAVID P President and CEO President and CEO Jul 27 Buy 3.80 19,737 75,001 1,028,460 07/29/22